Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Respiratorius

1.73 SEK

+4.55 %

Less than 1K followers

RESP

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+4.55 %
-8.97 %
-52.08 %
-78.38 %
-73.46 %
-53.13 %
-96.46 %
-99.03 %
-87.95 %

Respiratorius is a research company focused on the development of drug candidates for the treatment of cancer, and especially aggressive lymphoma. The company was originally established in 1999 as a spin-off from Lund University. The business is located in Sweden, where research is conducted in-house but also through international partners. The company is headquartered in Lund.

Read more
Market cap
13.63M SEK
Turnover
5.38K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
10/2
2026

Annual report '25

All
Press releases
ShowingAll content types
Regulatory press release12/4/2025, 7:57 AM

Respiratorius: Valberedning inför årsstämman 2026 utsedd

Respiratorius
Regulatory press release11/11/2025, 7:31 AM

Respiratorius: Delårsrapport 3, 2025

Respiratorius
Regulatory press release9/16/2025, 1:51 PM

Sista dag för handel med BTA i Respiratorius

Respiratorius

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release9/11/2025, 3:07 PM

Respiratorius offentliggör utfall av inlösen av teckningsoptioner serie TO2

Respiratorius
Regulatory press release9/6/2025, 7:38 AM

Respiratorius offentliggör utfall i företrädesemission

Respiratorius
Press release9/2/2025, 1:06 PM

Respiratorius VD ökar sitt deltagande i pågående företrädesemission - bolaget erhåller bekräftande FDA-protokoll och påminner om viktiga datum

Respiratorius
Regulatory press release9/1/2025, 6:32 AM

Respiratorius Receives Meeting Minutes from FDA Pre-IND Meeting

Respiratorius
Regulatory press release9/1/2025, 6:32 AM

Respiratorius erhåller mötesprotokoll från FDA:s pre-IND-möte

Respiratorius
Press release8/28/2025, 6:14 AM

BioStock: Läkare vill förskriva Respiratorius VAL001

Respiratorius
Regulatory press release8/20/2025, 6:30 AM

Respiratorius offentliggör informationsdokument avseende företrädesemission och information om TO2

Respiratorius
Regulatory press release8/12/2025, 6:40 AM

Respiratorius: Halvårsrapport 2025

Respiratorius
Regulatory press release8/12/2025, 6:35 AM

Respiratorius beslutar om en företrädesemission om cirka 18,9 MSEK

Respiratorius
Regulatory press release8/12/2025, 6:30 AM

Respiratorius has conducted a pre-IND meeting with the FDA

Respiratorius
Regulatory press release8/12/2025, 6:30 AM

Respiratorius har genomfört pre-IND-möte med FDA

Respiratorius
Regulatory press release6/18/2025, 6:18 AM

Respiratorius beviljas pre-IND-möte med FDA för VAL001

Respiratorius
Regulatory press release6/18/2025, 6:18 AM

Respiratorius Granted Pre-IND Meeting with FDA for VAL001

Respiratorius
Regulatory press release5/27/2025, 12:33 PM

Respiratorius: Notice of Allowance for European Patent on VAL001 Formulation

Respiratorius
Regulatory press release5/27/2025, 12:33 PM

Respiratorius: Godkännande av europeiskt patent för formuleringen av VAL001

Respiratorius
Regulatory press release5/21/2025, 1:55 PM

Kommuniké från årsstämma den 21 maj 2025 i Respiratorius AB (publ)

Respiratorius
Regulatory press release5/21/2025, 12:10 PM

Respiratorius: Delårsrapport 1, 2025

Respiratorius
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.